(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 209.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Immunitybio's revenue in 2025 is $14,745,000.On average, 3 Wall Street analysts forecast IBRX's revenue for 2025 to be $80,115,173,727, with the lowest IBRX revenue forecast at $78,107,024,378, and the highest IBRX revenue forecast at $84,064,050,495. On average, 3 Wall Street analysts forecast IBRX's revenue for 2026 to be $199,750,692,491, with the lowest IBRX revenue forecast at $158,194,034,514, and the highest IBRX revenue forecast at $233,501,768,683.
In 2027, IBRX is forecast to generate $382,788,427,614 in revenue, with the lowest revenue forecast at $307,469,598,697 and the highest revenue forecast at $478,183,629,361.